Recent progress in cancer therapy with radiolabeled monoclonal antibodies.
"Progress in the use of RAIT for cancer therapy has been slow but steady, involving the reengineerin1g of antibodies (reducing murine component, altering size and clearance properties), and pretargeting methods for improvving tumor:blood and tumor:organ ratios are continuing to evolve".